List of quality statements
Quality statement 2 updates and replaces quality statement 7: risk assessment – pre-eclampsia in NICE's quality standard on antenatal care.
Statement 1 Women of childbearing potential with treated hypertension are given information annually about safe antihypertensive treatment during pregnancy.
Statement 3 Pregnant women taking antihypertensive medication have a blood pressure target of 135/85 mmHg or less.
Statement 4 Pregnant women with severe hypertension are admitted for a full assessment, carried out by a healthcare professional trained in managing hypertension in pregnancy.
Statement 5 Women with pre-eclampsia who have severe hypertension or are at a high risk of adverse events, or if there are any clinical concerns are admitted to hospital and monitored.
Statement 6 Women with pre-eclampsia have a senior obstetrician involved in any decisions about the timing of birth.
Statement 7 Women who have had hypertension in pregnancy have a plan for ongoing antihypertensive management included in their postnatal care plan, which is communicated to their GP when they are transferred to community care after the birth.
Statement 8 Women who have had gestational hypertension or pre-eclampsia discuss future pregnancy and lifetime cardiovascular risks during a medical review at their 6–8 week postnatal medical check.
 Although this use is common in UK clinical practice, at the time of publication (July 2019), aspirin did not have a UK marketing authorisation for this indication. Community pharmacies cannot legally sell aspirin as a pharmacy medicine for prevention of pre-eclampsia in pregnancy in England. Aspirin for this indication must be prescribed. The prescriber should see the summary of product characteristics for the manufacturer's advice on use in pregnancy. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.